Pacira holder plans sale of 4,000 shares

Pacira BioSciences shareholder plans a modest stock sale under Rule 144.

Rhea-AI Filing Summary

Pacira BioSciences shareholder plans a modest stock sale under Rule 144. A holder filed to sell 4,000 shares of Pacira common stock on NASDAQ through Fidelity Brokerage Services LLC, with an indicated aggregate market value of $84,219.34.

The shares were acquired on 02/01/2026 through restricted stock vesting from the issuer as compensation, with payment recorded the same day. The notice also discloses that the same person sold 1,416 common shares on 01/05/2026 for gross proceeds of $34,323.84. Common shares outstanding for this class are listed as 43,021,275.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does Pacira (PCRX)'s latest Form 144 filing disclose?

The Form 144 shows a Pacira shareholder intends to sell 4,000 common shares on NASDAQ. The shares, valued at $84,219.34, were acquired via restricted stock vesting on February 1, 2026, and follow a prior 1,416-share sale in January 2026.

How many Pacira (PCRX) shares are covered by this Rule 144 sale?

The filing covers a planned sale of 4,000 Pacira common shares. These shares are to be sold through Fidelity Brokerage Services LLC on NASDAQ, with an indicated aggregate market value of $84,219.34, based on the price information included in the notice.

How did the seller in Pacira (PCRX)'s Form 144 acquire the shares?

The 4,000 Pacira shares were acquired on February 1, 2026, through restricted stock vesting from the issuer as compensation. The filing lists both the acquisition date and payment date as February 1, 2026, and identifies the issuer as the source.

What prior Pacira (PCRX) stock sales does the Form 144 report?

The notice reports that the same person sold 1,416 Pacira common shares on January 5, 2026. Those earlier sales generated gross proceeds of $34,323.84. This disclosure covers all sales in the past three months required to be aggregated under Rule 144.

Which broker and exchange are used for this Pacira (PCRX) share sale?

The planned 4,000-share Pacira sale is to be executed through Fidelity Brokerage Services LLC. The filing lists NASDAQ as the securities exchange where the common shares will be sold and provides Fidelity’s Smithfield, Rhode Island business address.

How many Pacira (PCRX) common shares are shown as outstanding?

For the class of common stock involved in this notice, the filing lists 43,021,275 shares outstanding. This figure provides context for the class of securities but is separate from the specific 4,000 shares covered by the planned Rule 144 sale.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 02/02/2026 - 04:12 PM Learn about SEC filing dates

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0001545439
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	Pacira BioSciences, Inc.
SEC File Number	001-35060
Address of Issuer	2000 SIERRA POINT PARKWAY SUITE 900 BRISBANE CALIFORNIA 94005
Phone	650-242-8052
Name of Person for Whose Account the Securities are To Be Sold	RIKER LAUREN
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Officer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Fidelity Brokerage Services LLC 900 Salem Street Smithfield RI 02917	4000	84219.34	43021275	02/02/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	02/01/2026	Restricted Stock Vesting	Issuer			4000	02/01/2026	Compensation

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Lauren B. Riker 2000 Sierra Point Parkway Suite 900 Brisbane CA 94005	Common	01/05/2026	1416	34323.84

144: Remarks and Signature

Remarks
Date of Notice	02/02/2026
Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1	06/13/2025
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	/s/Wade Moss, as a duly authorized representative of Fidelity Brokerage Services LLC, as attorney-in-fact for Lauren B. Riker
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)